Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer

• Published in: British journal of cancer Vol. 76; no. 7; pp. 939 - 942
• Main Authors: KYLMÄLÄ, T, TAUBE, T, TAMMELA, T. L. J, RISTELI, L, RISTELI, J, ELOMAA, I
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.01.1997
• Subjects: Administration, Oral; Aged; Aged, 80 and over; Analgesics; Analgesics, Non-Narcotic - administration & dosage; Analgesics, Non-Narcotic - adverse effects; Analgesics, Non-Narcotic - therapeutic use; Biological and medical sciences; Bone Neoplasms - metabolism; Bone Neoplasms - secondary; Clodronic Acid - administration & dosage; Clodronic Acid - adverse effects; Clodronic Acid - therapeutic use; Collagen - metabolism; Double-Blind Method; Humans; Injections, Intravenous; Male; Medical sciences; Middle Aged; Neuropharmacology; Pain - drug therapy; Pain - metabolism; Peptide Fragments - blood; Pharmacology. Drug treatments; Procollagen - blood; Prospective Studies; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Human; Urinary system disease; Intravenous administration; Prostate disease; Diseases of the osteoarticular system; Oral administration; Malignant tumor; Chemotherapy; Randomization; Analgesic; Pain; Treatment; Double blind study; Advanced stage; Bone; Male genital diseases; Prostate
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1997.488

Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by oral treatment (1.6 g day[-1]) for 12 months. Skeletal pain relief was only about 10% better in the clodronate than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only.